Publications
Inomagen Awarded NIH/NHLBI Phase II SBIR Grant Providing Up to $2.9 Million to Advance Gene Therapy for Atrial Fibrillation
Inomagen Therapeutics has been awarded a two-year NIH/NHLBI Phase II SBIR grant providing up to $2.9 million to advance its investigational non-viral gene therapy for atrial fibrillation toward a future IND application.
Inomagen Awarded $3.67 million NIH SBIR Fast Track Grant to Develop Gene Therapy for Atrial Fibrillation Identified major molecular mechanisms that contribute to AF in a majority of patients with Atrial Fibrillation
Attenuation of Oxidative Injury With Targeted Expression of NADPH Oxidase 2 Short Hairpin RNA Prevents Onset and Maintenance of Electrical Remodeling in the Canine Atrium
A Novel Gene Therapy Approach to Atrial Fibrillation
Gene therapy for atrial fibrillation - How close to clinical implementation?
Amar Trivedi, Jacob Hoffman, Rishi Arora *Feinberg Cardiovascular and Renal Research Institute, Northwestern University e Feinberg School of Medicine, United States of America